[1. Pramoolsinsap C, Pukrittayakamee S, Desakorn V. Hepatitis B problem in Thailand. Southeast Asian J Trop Med Public Health. 1986; 17:219-28.]Search in Google Scholar
[2. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000; 15:1356-61.10.1046/j.1440-1746.2000.0150121356.x11197043]Open DOISearch in Google Scholar
[3. Poovorawan Y, Sanpavat S, Pongpunglert W, Chumdermpadetsuk S, Sentrakul P, Vandepapeliere P, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J. 1992; 11:816-21.10.1097/00006454-199210000-000021408478]Open DOISearch in Google Scholar
[4. Poovorawan Y, Chatchatee P, Chongsrisawat V. Epidemiology and prophylaxis of viral hepatitis: a global perspective. J Gastroenterol Hepatol. 2002; 17 (Suppl): S155-66.10.1046/j.1440-1746.17.s1.4.x12000601]Open DOISearch in Google Scholar
[5. Lau GK, Carman WF, Locarnini SA, Okuda K, Lu ZM, Williams R, et al. Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. J Gastroenterol Hepatol. 1999; 14:3-12.10.1046/j.1440-1746.1999.01812.x10029271]Open DOISearch in Google Scholar
[6. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000; 15 (Suppl):E25-30.10.1046/j.1440-1746.2000.02097.x10921378]Open DOISearch in Google Scholar
[7. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004; 53:744-9.10.1136/gut.2003.020263177405515082595]Open DOISearch in Google Scholar
[8. Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2000; 15 Suppl:E20-4.10.1046/j.1440-1746.2000.02123.x10921377]Open DOISearch in Google Scholar
[9. Zacharakis GH, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, et al. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/ECproject). J Med Virol. 2005; 77:173-9.10.1002/jmv.2043416121378]Open DOISearch in Google Scholar
[10. Leung N. Nucleoside analogues in the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2000; 15 (Suppl):E53-60.10.1046/j.1440-1746.2000.02103.x10921383]Open DOISearch in Google Scholar
[11. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat. 2002; 9: 393-9.10.1046/j.1365-2893.2002.00388.x12431200]Open DOISearch in Google Scholar
[12. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119: 172-80.10.1053/gast.2000.8559]Open DOISearch in Google Scholar
[13. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol. 2006; 4:666-76.10.1016/j.cgh.2006.03.017]Open DOISearch in Google Scholar
[14. Yuen MF, Lai CL. Recommendations and potential future options in the treatment of hepatitis B. Expert Opin Pharmacother. 2006; 7:2225-31.10.1517/14656566.7.16.2225]Search in Google Scholar
[15. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006; 26:130-41.10.1055/s-2006-939751]Open DOISearch in Google Scholar
[16. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1:431-5.10.1002/hep.1840010511]Open DOISearch in Google Scholar
[17. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45:1056-75.10.1002/hep.21627]Open DOISearch in Google Scholar
[18. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46:254-65.10.1002/hep.21698]Open DOISearch in Google Scholar
[19. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 25 (Suppl 1):3-8.10.1055/s-2005-915644]Open DOISearch in Google Scholar
[20. Ganem D, Prince AM. Hepatitis B virus infection- natural history and clinical consequences. N Engl J Med. 2004; 350:1118-29.10.1056/NEJMra031087]Open DOISearch in Google Scholar
[21. Ribeiro RM, Lo A, Perelson AS. Dynamics of hepatitis B virus infection. Microbes Infect. 2002; 4:829-35.10.1016/S1286-4579(02)01603-9]Open DOISearch in Google Scholar
[22. Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008; 48:335-52.10.1016/j.jhep.2007.11.011]Open DOISearch in Google Scholar
[23. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95.10.1056/NEJMoa043470]Open DOISearch in Google Scholar
[24. Cooksley G. The treatment of hepatitis B e antigenpositive chronic hepatitis B with pegylated interferon. J Hepatol. 2003; 39 (Suppl 1):S143-5.10.1016/S0168-8278(03)00327-1]Open DOISearch in Google Scholar
[25. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365 (9454):123-9.10.1016/S0140-6736(05)17701-0]Search in Google Scholar
[26. Bedossa P B-SP, Callard P, Chevallier M, Degott C, Deugnier Y, et al. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994; 20:15-20.10.1002/hep.1840200104]Open DOISearch in Google Scholar
[27. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol. 1996; 25:649-54.10.1016/S0168-8278(96)80234-0]Open DOISearch in Google Scholar
[28. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut. 2007; 56:699-705.10.1136/gut.2005.089722194215217127704]Open DOISearch in Google Scholar
[29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008; 47:428-34.10.1002/hep.2206518220290]Open DOISearch in Google Scholar
[30. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142:240-50.10.7326/0003-4819-142-4-200502150-0000615710957]Open DOISearch in Google Scholar
[31. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001; 33:1527-32.10.1053/jhep.2001.2508411391543]Search in Google Scholar
[32. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004; 19:1276-82.10.1111/j.1440-1746.2004.03428.x15482535]Open DOISearch in Google Scholar
[33. Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004; 19:323-9.10.1111/j.1365-2036.2004.01845.x14984379]Open DOISearch in Google Scholar
[34. Hui CK, Lau GK. Treatment of hepatitis B e antigennegative patients. Curr Treat Options Gastroenterol. 2007; 10:474-82.10.1007/s11938-007-0047-618221608]Search in Google Scholar
[35. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005; 42:121-9.10.1002/hep.2076015962291]Open DOISearch in Google Scholar
[36. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004; 40:883-91.10.1002/hep.1840400418]Open DOISearch in Google Scholar
[37. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351:1206-17.10.1056/NEJMoa04043115371578]Open DOISearch in Google Scholar
[38. Zhang DZ. [Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B]. Zhonghua Gan Zang Bing Za Zhi. 2007; 15:876-7.]Search in Google Scholar
[39. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban- Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007; 5:890-7.10.1016/j.cgh.2007.05.00417632041]Open DOISearch in Google Scholar
[40. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat. 2007; 14:751-66.10.1111/j.1365-2893.2007.00865.x215615117927611]Open DOISearch in Google Scholar
[41. Gish RG. Improving outcomes for patients with chronic hepatitis B. Hepatol Res. 2007; 37 (s1):S67-78.10.1111/j.1872-034X.2007.00108.x17627639]Open DOISearch in Google Scholar
[42. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008; 15:137-45.10.1007/s11373-007-9225-818058038]Open DOISearch in Google Scholar
[43. Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol. 2007; 5:1454-61.10.1016/j.cgh.2007.08.008264578817977800]Open DOISearch in Google Scholar
[44. Perrillo RP, Jacobson IM. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis. 2007; 27 (Suppl 1):3-8. 10.1055/s-2007-98469417701844]Open DOISearch in Google Scholar